Condition
MIBC clinical trials and research
As of November 12, 2026, Find a Trial lists 4 MIBC clinical trials that are recruiting, at sites in 3 countries (most in China (2), Egypt (1), Germany (1)). 1 was first registered in the last 30 days. By phase: Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1New in 30 days
- 3Countries
Newest MIBC clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer | — | Munich, Bavaria and 2 other locations | Recruiting | Oct 13, 2026 |
| Neoadjuvant RC48 plus gemcitabine vs RC48 plus toripalimab for muscle-invasive bladder cancer | Phase 3 | Hefei, Anhui and 21 other locations | Recruiting | Jul 9, 2026 |
| Using multiparametric MRI to predict early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer | — | Asyut | Recruiting | Oct 2, 2025 |
| Monitoring recurrence of urothelial carcinoma using urinary tests | — | Beijing, Beijing Municipality | Recruiting | May 28, 2025 |
All recruiting trials (4)
-
Peripheral neuropathy during perioperative therapy with enfortumab vedotin and pembrolizumab in muscle-invasive urothelial cancer
This study follows adults with muscle-invasive urothelial cancer to see how nerve-related side effects develop when people receive enfortumab vedotin and pembrolizumab around surgery as part of standard care.
-
Neoadjuvant RC48 plus gemcitabine vs RC48 plus toripalimab for muscle-invasive bladder cancer
This trial tests whether RC48 with gemcitabine works as well as RC48 with toripalimab as a pre-surgery treatment for muscle-invasive bladder cancer in adults.
-
Using multiparametric MRI to predict early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
This project will try multiparametric MRI scans to see if early changes can predict which people with muscle-invasive bladder cancer will respond to cisplatin-based neoadjuvant chemotherapy.
-
Monitoring recurrence of urothelial carcinoma using urinary tests
This study is testing if urine tests can help track the return of urothelial carcinoma in patients with different types of bladder and kidney cancer.
Related topics
Quick answers
How many MIBC clinical trials are recruiting right now?
4, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (2 trials), Egypt (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.